Hyundai Bioscience completes 10 billion won convertible bond issuance for Penitrium acquisition, minimal dilution under 1%
Hyundai Bioscience completed the issuance of 10 billion won in 12th unsecured private convertible bonds with a payment date of June 23, 2026.
The conversion price of 10,201 won represents a 19.6% premium over the current stock price of 8,530 won, and a one-year conversion and split lock-up limits short-term dilution risk.
Funds will be used to acquire shares of Penitrium Bioscience, making mid- to long-term business synergy the key factor.
[AI Summary]The capital raise is small at 1.2% of market cap with limited dilution due to the premium and lock-up, but uncertainty in the target's valuation and governance opacity from a private equity counterparty pose investment risks.